Private equity curbs hit healthcare as new state laws bite US markets

California and Oregon have moved from legislation to enforcement in efforts to limit private equity’s influence over medical practices. The measures focus on strengthening corporate practice of medicine rules, expanding transaction notice requirements and narrowing the operational scope of management services organizations (MSOs) to protect clinical autonomy.

The developments unfolded with Oregon’s Senate Bill 951 (SB 951) signed on June 9, 2025; the law bars MSOs and related parties from exercising de facto control over clinical and key administrative functions and sets compliance deadlines of January 1, 2026 for new arrangements and January 1, 2029 for existing ones. In California, Assembly Bill 1415 (AB 1415) and SB 351 tighten reporting and CPOM-related restrictions, increasing state oversight of certain private-equity-backed transactions.

Market impact has been immediate: healthcare M&A timelines have lengthened, deal structures are being reworked to segregate clinical governance from investor control, and some acquisition models that relied on broad MSO authority face higher compliance costs. Buyers and platforms that cannot convincingly demonstrate physician-led governance or safeguards for continuity of care are more likely to face state review or conditions. Valuation multiples and transaction premiums may be pressured where regulatory risk is material.

In the broader economic and policy context, these state-level moves reflect growing political and public scrutiny of private equity in healthcare amid concerns over patient access, staffing and costs. Regulators are prioritizing substance over form—looking at who actually controls clinical decisions rather than legal wrappers—so traditional PC–MSO safe harbors are less reliable. The trend also signals potential for other states to adopt similar guardrails.

Analysts expect more granular pre-close reviews, higher due diligence on governance and payer contracts, and deal terms that include enforceable commitments on staffing, capital spending and limits on dividend recaps. Private equity investors will likely favor minority or joint-venture structures, clearer firewalling between clinical and business functions, and documented quality commitments to secure approvals and preserve asset performance. The near-term outlook points to a more cautious M&A market in healthcare, with durability hinging on demonstrable protections for clinical autonomy and patient access.